# LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

> **NCT01986426** · PHASE1 · COMPLETED · sponsor: **Lytix Biopharma AS** · enrollment: 80 (estimated)

## Conditions studied

- Cancer
- Melanoma
- Breast Cancer
- Head and Neck Cancer
- Lymphoma
- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** LTX-315 consecutive lesions
- **DRUG:** LTX-315
- **DRUG:** LTX-315 + ipilimumab
- **DRUG:** LTX-315 + pembrolizumab

## Key facts

- **NCT ID:** NCT01986426
- **Lead sponsor:** Lytix Biopharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-04
- **Final completion:** 2018-08-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986426, "LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01986426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*